Concepedia

Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer

Rodney P. Rocconi, Erin Stevens, Justin Bottsford-Miller, Sharad Ghamande, Jeffrey Elder, Leslie DeMars, Adnan Munkarah, Phylicia Aaron, Laura Stanbery, Gladice Wallraven,

Cancer Gene Therapy · 2021 · 23 citations · 36 references

DOI

Concepts

References

36

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

Nicholas McGranahan, Andrew J.S. Furness, Rachel Rosenthal et al. · Science · 2016 · 3.1K citations · Full text

, , +17

Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

Eiichi Sato, Sara H. Olson, Jiyoung Ahn et al. · Proceedings of the National Academy of Sciences · 2005 · 2.4K citations · Full text

, , +17

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

Robert A. Burger, Mark F. Brady, Michael A. Bookman et al. · New England Journal of Medicine · 2011 · 2.4K citations · Full text

, , +11

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

Éric Pujade-Lauraine, Felix Hilpert, B. Weber et al. · Journal of Clinical Oncology · 2014 · 1.6K citations · Full text

, , +17

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

Thomas Powles, Ignacio Durán, Michiel S. van der Heijden et al. · The Lancet · 2017 · 1.4K citations · Full text

, , +12